Fresenius Medical Care (ETR:FME) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?
Fresenius Medical Care (ETR:FME) shares have crossed above their 200-day moving average of €42.56, trading at €45.57 with a market cap of $13.79 billion. The stock has a PE ratio of 20.93 and a beta of 0.86. Analysts currently rate it as a Hold, but suggest that there are better investment options available. The company specializes in dialysis services for renal disease patients across various regions.
Shares of Fresenius Medical Care AG (ETR:FME - Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of €42.56 ($47.29) and traded as high as €45.73 ($50.81). Fresenius Medical Care shares last traded at €45.57 ($50.63), with a volume of 408,811 shares traded.
Get Fresenius Medical Care alerts:
Fresenius Medical Care Price Performance
The stock's 50 day moving average is €45.58 and its two-hundred day moving average is €42.56. The company has a debt-to-equity ratio of 82.24, a quick ratio of 0.80 and a current ratio of 1.37. The stock has a market capitalization of $13.79 billion, a PE ratio of 20.93, a price-to-earnings-growth ratio of 0.42 and a beta of 0.86.
Fresenius Medical Care Company Profile
(Get Free Report)Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Recommended Stories
- Five stocks we like better than Fresenius Medical Care
- What Are Dividend Challengers?
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- How Technical Indicators Can Help You Find Oversold Stocks
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- What is a buyback in stocks? A comprehensive guide for investors
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Fresenius Medical Care Right Now?
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
